Overview / Abstract: |
STATEMENT OF NEED Hodgkin lymphoma (HL) is a rare malignancy involving the lymph nodes and lymphatic system, with 8,500 new cases diagnosed and accounting for 1,050 deaths each year in the United States. In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during middle age, and is followed by another peak in adults older than 55. There are 2 main types of HL: classical HL, which accounts for 95% of cases in Western countries and is characterized by the presence of Reed-Sternberg cells, and nodular lymphocyte-predominant HL, which lacks these cells. The last few decades have seen significant progress in the management of patients with HL, leading to improved outcomes. The 5-year overall survival rate is approximately 90% for early-stage disease. However, challenges remain, such as improving remission rates in patients with advanced disease, who experience 5-year overall survival of approximately 65%, and improving quality of life of survivors, who may be at risk for secondary malignancies and late toxicities. TARGET AUDIENCE Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with classical Hodgkin lymphoma (cHL). LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1. Describe factors that increase the risk for cHL treatment failure and the development of acute and late toxicities |
Expiration |
Jan 20, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Monograph, Online |
Credits / Hours |
1.0 |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Craig H. Moskowitz, MD (Chairperson) Kami Maddocks, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Seattle Genetics. |
Keywords / Search Terms |
i3 Health i3 Health, Hodgkin lymphoma, HL, hematologic malignancies, lymphoma, oncology, hematology, CE, CME, free CE, free CME, ILNA points Free CE CME |